The pharmaceutical industry is facing a period rich with opportunity and uncertainty as businesses are confronted by the need to generate growth in a mature, competitive market while faced with increasing pricing pressures and contracting margins.
Blockbuster patent expiries and the entry of biosimilar products has seen innovative pharmaceutical companies change direction, resulting in a blurring of traditional lines in the market. Coupled with unprecedented collaboration between global players, this is driving innovative approaches to commercialising IP and transformative asset-driven transactions.
Combining deep scientific and technical knowledge, we apply our commercial nous and experience to anticipate and deliver innovative, value-enhancing solutions.
We partner with our clients at every level of their businesses to help them achieve their goals: from strategic advice on "bet-the-company" transactions and disputes to merger control, regulatory investigations, commercial contracts and licensing.
Our intellectual property lawyers, the majority of whom have scientific or engineering backgrounds, understand that innovation is at the heart of the pharmaceutical industry. We help the world's leading pharmaceutical companies to use intellectual property to achieve commercial outcomes and competitive advantage, and have acted on some of the most complex transactions and disputes in the market.
Our integrated pharmaceuticals team spans our network of offices, and together with our preferred, trusted local law firms, work as one to provide commercial solutions—wherever you operate.
A global innovator pharmaceuticals company
Advising in an ICC arbitration seated in Singapore. This concerned a dispute with another global pharmaceuticals company arising out of a co-promotion agreement. Following a two-week merits hearing, our client won a significant award.
Advising AbbVie on its proposed US$55 billion takeover of Shire, a FTSE-100 pharmaceutical company
Claris Life Sciences Limited
Acting for Claris Life Sciences Limited on the sale of its Global Generic Injectables Business to Baxter for US$ 625 million
Representing Gilead in the successful defence of claims for patent infringement in both the UK and Australia brought by Idenix. These claims related to Gilead’s cure for Hepatitis C, sofosbuvir, worth over $10 billion in worldwide annual sales
Representing Ariosa, a subsidiary of Roche, in patent infringement proceedings brought against it in both the English High Court and the Australian Federal Court in relation to its Harmony® non-invasive prenatal test
Advising Diageo in relation to product liability issues arising from the distribution of Thalidomide in the late 1950s/early 1960s. This is a major ongoing tort action with proceedings in multiple jurisdictions
Alan specialises in public and private cross-border mergers and acquisitions, restructurings, joint ventures and partnership matters, acting for international corporates, investment banks and professional services firms.